FDA announces actions to accelerate drug development
• On June 22, the FDA announced several initiatives to accelerate both early- and late-stage drug development as part of the Department of Health and Human Services' "Operation TrailBlazer." • A key component is a new drug pilot program designed to shorten the timeline between initial drug identification and first-in-human clinical studies. • The program aims to establish a network of qualified research institutions, including academic medical centers and contract research organizations, to collaborate with sponsors on protocol development.
aha.org
